Avantax Advisory Services Inc. Grows Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Avantax Advisory Services Inc. increased its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 8.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 106,373 shares of the biotechnology company’s stock after purchasing an additional 8,109 shares during the quarter. Avantax Advisory Services Inc.’s holdings in ADMA Biologics were worth $1,824,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. lifted its position in shares of ADMA Biologics by 85.8% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 94,938 shares of the biotechnology company’s stock worth $1,898,000 after buying an additional 43,836 shares during the last quarter. Natixis Advisors LLC purchased a new stake in ADMA Biologics in the third quarter valued at $345,000. Mutual of America Capital Management LLC acquired a new position in ADMA Biologics in the third quarter valued at $701,000. Thrivent Financial for Lutherans purchased a new position in shares of ADMA Biologics during the third quarter worth about $3,802,000. Finally, First Turn Management LLC acquired a new stake in shares of ADMA Biologics during the third quarter worth about $13,293,000. 75.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $18.67 on Tuesday. ADMA Biologics, Inc. has a one year low of $5.88 and a one year high of $23.64. The stock has a market capitalization of $4.41 billion, a price-to-earnings ratio of 66.68 and a beta of 0.60. The company has a 50-day simple moving average of $16.66 and a 200-day simple moving average of $17.97. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.